Health Care • Biotechnology: Pharmaceutical Preparations
$4.21 ▼ -0.07
(-1.64%)
MKT CAP: $656.0M • VOL: 2.53M
52W L $4 52W H $5
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$4
MEDIAN
$5
MEAN
$5
HIGH
$6
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABUS TAPE
ABUS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $5.09 | $4.84 | 2025-02-14 | $3.83 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $5.30 | $4.97 | 2025-02-06 | $3.96 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $4.80 | $4.63 | 2025-01-29 | $4.04 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $4.29 | — | 2025-01-17 | $4.13 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $3.70 | $4.00 | 2025-01-09 | $3.75 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $5.01 | $4.38 | 2024-12-18 | $3.66 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $4.08 | $4.25 | 2024-12-04 | $3.92 | -4.3% | 48% | C |